Stock·NYSE·Healthcare
Abbott Laboratories (ABT)
- Market cap
- $182.70B
- P/E
- 33.66
- Dividend yield
- 2.40%
- Street target
- $120.00median of 28 analysts
- 52-week range
- $81.97 $132.03
The short version
Where ABT stands today, in four lines, and what CleaRank Financial AI makes of it.
ABT at a glance
Abbott Laboratories (ABT): Buy, 63/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($102.80 and $105.87).
- Earnings ABT beat estimates in 4 of its last 7 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $48.6M and bought $4.4M over the last 18 months.
- Valuation P/E of 33.7 against 31.9 for the Healthcare sector: broadly in line with peers (+6%).
Figures as of October 16, 2026.
CleaRank Financial AI
ABT earns a CleaRank rating of Buy with a model score of 63/100.
The analysts' outlook pushes that score up the most. Here, 24 of 28 analysts rate the stock a buy and the median target is 14.4% above the price. Momentum is the main drag, since the MACD line is negative. The trend is mixed: the price sits 0.93% under its 50-day average of $105.87 yet 2.03% over its 200-day average of $102.80. The price fell 17.82% across the past year.
Only on CleaRank
Figures we compute ourselves from ABT's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
2/4Price above its 50-day average ›
The price of $104.89 is 0.9% below the 50-day simple moving average of $105.87.Price above its 200-day average ›
The price is 2.0% above the 200-day simple moving average of $102.80.50-day average above the 200-day ›
The 50-day average ($105.87) is 3.0% above the 200-day average ($102.80), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 46% of its 52-week range, between $81.97 and $132.03.
ABT share price
Pick a period: each tab shows how far ABT has moved over it, to the last close.
Today's trading
Where ABT sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 33.66 is 5.5% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 3.91 is 15.1% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $5.4B on revenue of $46.6B, a net margin of 11.6%.Beat estimates in most recent reports ›
ABT beat the EPS estimate in 4 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 2.40%, or $2.52 a share a year.
Key statistics
The headline figures for ABT.
As of October 16, 2026, ABT trades at $104.89, with a market value of $182.70B, a P/E ratio of 33.66 and a dividend yield of 2.40%.
What the numbers say
CleaRank Financial AI's reading of ABT's valuation, growth and risks.
Abbott Laboratories (ABT) carries a trailing P/E of 33.66. That is 5.5% above the Healthcare sector median of 31.9, and the Peer Benchmarking card calls the multiple broadly in line with peers. On sales, the P/S of 3.91 sits 15.0% above the sector median of 3.4. Market value stands at $182.7B, with trailing earnings of $3.11 per share.
Revenue expanded 13.00% across the latest year, running 4.9 percentage points faster than the Healthcare sector median of 8.1%. On profitability, the net margin stands at 11.65% and the operating margin at 14.71%. Return on equity is 10.58%, which is above the sector median of 7.3%. Debt-to-equity comes in at 0.63, and the trailing dividend yield is 2.40%, equal to $2.52 a share each year.
ABT's most recent earnings report, dated July 16, 2026, showed $1.31 per share against an estimate of $1.28. That beat the estimate by 2.34%. In the next session the shares moved up 1.87%.
ABT beat the EPS estimate in 4 of its last 7 reports, though the stock still fell in the first session after 1 of those 4 beats. Analysts' average EPS estimate for this fiscal year is $5.52, which would be growth of 7.1%, and $6.07 for next year (growth of 9.9%).
ABT typically moves 1.33% on an average day. The price is 20.56% under its 52-week high of $132.03.
ABT against the Healthcare sector
How ABT compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (6% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 6, 2025, ABT has lost 21.2% against a gain of 31.4% for XLV.
Performance against XLV
ABT and the Healthcare sector fund over the same days.
Revenue and earnings
How much ABT sells, and how much of it becomes profit.
Revenue growth: Revenue grew 5.7% in FY2025 to $44.3B, from $42.0B a year earlier.
Profit margin: The net margin was 14.7% in FY2025, down from 31.9% the year before.
Profitable: ABT earned $6.5B in FY2025.
Earnings reality check
Did ABT beat what analysts expected, and how did the stock react?
Earnings record: ABT beat the analyst estimate in 4 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 16, 2026after close | $1.28 | $1.31 | +2.34% | +1.87% | +1.94% |
| Jan 22, 2026after close | $1.49 | $1.50 | +0.67% | -1.10% | -2.32% |
| Oct 15, 2025after close | $1.30 | $1.30 | +0.00% | -1.41% | -1.16% |
| Jul 17, 2025after close | $1.26 | $1.26 | +0.00% | +2.62% | +4.26% |
| Apr 16, 2025after close | $1.07 | $1.09 | +1.87% | +0.99% | -0.25% |
| Jan 22, 2025after close | $1.34 | $1.34 | +0.00% | +4.62% | +8.56% |
| Oct 16, 2024after close | $1.20 | $1.21 | +0.83% | +0.06% | -0.69% |
As of October 16, 2026, ABT has beaten the analyst EPS estimate in 4 of its last 7 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 16, 2026, came in 2.34% above the estimate and the stock moved +1.87% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 59.0, in neutral territory.RSI above 50 ›
An RSI of 59.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of ABT
The score, the reasoning behind it, and what could move the price next.
ABT is caught between its two moving averages. At $104.89, the stock sits 2.03% above its 200-day average of $102.80 but 0.93% below its 50-day average of $105.87. Across its 52-week range, running from $81.97 up to $132.03, the price stands at 46%.
The longer record is more mixed than the recent gains suggest. Over the past month the price climbed 2.47%, and over the past three months it added 4.18%, yet across the past year it dropped 17.82%. The 14-day RSI sits at 59.0, which is neutral territory, while the MACD line is negative, so momentum has not yet turned decisively.
Earnings beat ›
The July 16, 2026 report beat the EPS estimate by 2.34%, and the share price rose 1.87% in the first session after it.
Source: Earnings report, July 16, 2026Analyst upgrade ›
Rothschild & Co upgraded it to Buy from Neutral on October 2, 2026.
Source: Analyst action, Rothschild & Co, October 2, 2026
New analyst coverage ›
Barclays started coverage at Overweight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026
- The two closest levels matter most: the 50-day SMA at $105.87 sits above the price, and the 200-day SMA at $102.80 sits below it.
- The 14-day RSI stands at 59.0, which is neutral, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- The share price climbed 1.87% in the first session after the July 16, 2026 report. Across the last 7 reports, ABT has beaten estimates in 4 of them.
ABT sits above its 200-day average of $102.80 but below its 50-day average of $105.87, so the trend reads as mixed. A close above the 50-day would bring both signals up, while a close below the 200-day would bring both down. For now the price is wedged between the 200-day SMA ($102.80) beneath it and the 50-day SMA ($105.87) above it.
A 14-day RSI of 59.0 places the stock in neutral territory, inside the 40 to 60 band.
Technical indicators
Momentum and trend for ABT, from its daily closes.
As of October 16, 2026, with ABT at $104.89, its 14-day RSI is 59.0 (neutral territory), its 50-day simple moving average is $105.87 and its 200-day is $102.80.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ABT moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, ABT's 1-year correlation of daily returns is +0.13 with S&P 500 (SPY), -0.02 with Nasdaq 100 (QQQ), -0.05 with Bitcoin (BTC) and +0.05 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
24 of 28 analysts rate it a buy or strong buy, 4 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $120.00 is 14.4% above the price.More buy ratings than three months ago ›
24 of 28 rate it a buy now, against 20 of 27 three months ago.
ABT Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Initiates | Overweight |
| Oct 2, 2026 | Rothschild & Co | Upgrade | Buy |
| Sep 8, 2026 | TD Cowen | Reiterates | Buy |
| Aug 25, 2026 | TD Cowen | Maintains | Buy |
| Aug 21, 2026 | TD Cowen | Maintains | Buy |
| Aug 14, 2026 | Citigroup | Maintains | Buy |
As of October 16, 2026, 28 Wall Street analysts cover ABT: 24 rate it a buy or strong buy, 4 a hold and 0 a sell or strong sell. Their 12-month price targets range from $103.00 to $135.00, with a median of $120.00, 14.4% above the price of $104.89.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ABT trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ABT's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ABT tends to move, against the market and on its own.
The long record
ABT's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.33% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 37.5%, from March 2025 to May 2026; the price is still 20.8% below that peak.Most 1-year holds ended higher ›
73% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $31,097, against $42,525 in the S&P 500 (SPY).
ABT Drawdowns & Recovery
As of October 16, 2026, ABT's worst peak-to-trough fall over the last 10 years with dividends reinvested was -37.5% (March 2025 to May 2026); it is still 20.8% below that peak, and 73% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ABT in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ABT trailed the S&P 500 over this period: $31,097 against $42,525.
A $10,000 investment in ABT in October 2016 would be worth about $31,097 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ABT, and which have not.
Strongest month, July: an average of +4.77%, up in 9 of 10 years.
Weakest month, March: an average of -3.04%, up in 1 of 10 years.
This month, October: has averaged -0.41%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ABT's strongest calendar month has been July (average +4.77%, up in 9 of 10 years) and its weakest March (average -3.04%, up in 1 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ABT, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ABT today could grow to about $21,052 by 2036 in the base case, with a 90th-percentile outcome near $55,732 and a 10th-percentile outcome around $7,952. The simulation models price only; at today's 2.40% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ABT Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $141 for ABT by 2030 in the base case, from $105 today (1.3x over 4 years). The 10th-percentile path ends near $76.32. These are outcomes of a Monte Carlo simulation run on ABT's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $83.05 | $113 | $154 | |
| 2028 | $78.76 | $122 | $188 | |
| 2029 | $76.94 | $131 | $224 | |
| 2030 | $76.32 | $141 | $261 | |
| 2031 | $76.45 | $152 | $303 |
Method: a lognormal simulation of ABT's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
ABT insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $4.4M on the open market and sold $48.6M.
As of October 16, 2026, ABT insiders reported 12 open-market sales worth $48.6M and 5 open-market purchases worth $4.4M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | John A. Mccoy Jr
Officer
|
Sell | 27 | $3.0K |
| Aug 25, 2026 | Robert B. Ford
Chief Executive Officer
|
Sell | 398.8K | $46.2M |
| Aug 25, 2026 | Robert B. Ford
Chief Executive Officer
|
Option | 398.8K | $21.5M |
| Aug 11, 2026 | Louis H Morrone
Officer
|
Sell | 5.9K | $642.5K |
| May 7, 2026 | John G. Stratton
Director
|
Buy | 2.0K | $173.6K |
| Apr 27, 2026 | Daniel J Starks
Director
|
Buy | 10.0K | $926.5K |
| Apr 24, 2026 | Nita M.d. Ahuja
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Claire Fontenot Babineaux
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Sally E Blount
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Kevin T Conroy
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Patricia Paola Gonzalez
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Michelle A Kumbier
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Darren W Mcdew
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Nancy Mckinstry
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Grady Michael G O
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Michael F Roman
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | Daniel J Starks
Director
|
Grant | 2.3K | - |
| Apr 24, 2026 | John G. Stratton
Director
|
Grant | 2.3K | - |
| Apr 23, 2026 | Philip P Boudreau
Chief Financial Officer
|
Buy | 2.2K | $201.3K |
| Mar 23, 2026 | Jacob A Orville
Officer
|
Grant | 13.3K | - |
| Mar 2, 2026 | Louis H Morrone
Officer
|
Sell | 1.1K | $132.2K |
| Mar 2, 2026 | Daniel Gesua Sive Salvadori
Officer
|
Sell | 885 | $102.3K |
| Mar 2, 2026 | Eric Shroff
Officer
|
Sell | 709 | $81.9K |
| Mar 2, 2026 | Mary K Moreland
Officer
|
Sell | 613 | $70.9K |
| Mar 2, 2026 | John A. Mccoy Jr
Officer
|
Sell | 585 | $67.6K |
| Mar 2, 2026 | Elizabeth C Cushman
General Counsel
|
Sell | 263 | $30.4K |
| Feb 24, 2026 | Philip P Boudreau
Chief Financial Officer
|
Grant | 28.0K | - |
| Feb 24, 2026 | Elizabeth C Cushman
General Counsel
|
Grant | 15.0K | - |
| Feb 24, 2026 | Lisa D Earnhardt
Officer
|
Grant | 27.1K | - |
| Feb 24, 2026 | Robert B. Ford
Chief Executive Officer
|
Grant | 83.5K | - |
| Feb 24, 2026 | John A. Mccoy Jr
Officer
|
Grant | 5.4K | - |
| Feb 24, 2026 | Mary K Moreland
Officer
|
Grant | 14.0K | - |
| Feb 24, 2026 | Louis H Morrone
Officer
|
Grant | 15.4K | - |
| Feb 24, 2026 | Daniel Gesua Sive Salvadori
Officer
|
Grant | 21.6K | - |
| Feb 24, 2026 | Christopher J Scoggins
Officer
|
Grant | 18.5K | - |
| Feb 24, 2026 | Eric Shroff
Officer
|
Grant | 10.9K | - |
| Feb 4, 2026 | Daniel J Starks
Director
|
Buy | 10.0K | $1.1M |
| Jan 23, 2026 | Robert B. Ford
Chief Executive Officer
|
Buy | 18.8K | $2.0M |
| Dec 11, 2025 | Daniel Gesua Sive Salvadori
Officer
|
Grant | 1.5K | $189.4K |
| Nov 25, 2025 | Eric Shroff
Officer
|
Sell | 1.6K | $203.0K |
| Aug 8, 2025 | Philip P Boudreau
Chief Financial Officer
|
Sell | 5.6K | $746.8K |
| Jun 27, 2025 | Elizabeth C Cushman
General Counsel
|
Grant | 3.8K | - |
| Apr 30, 2025 | Sally E Blount
Director
|
Sell | 2.6K | $337.1K |
| Apr 25, 2025 | Robert J Alpern
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Claire Fontenot Babineaux
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Sally E Blount
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Patricia Paola Gonzalez
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Michelle A Kumbier
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Darren W Mcdew
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Nancy Mckinstry
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Grady Michael G O
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Michael F Roman
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | Daniel J Starks
Director
|
Grant | 1.6K | - |
| Apr 25, 2025 | John G. Stratton
Director
|
Grant | 1.6K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.